Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CureVac N.V (CVAC) EBIT: 2018-2024

Historic EBIT for CureVac N.V (CVAC) over the last 7 years, with Dec 2024 value amounting to $189.9 million.

  • CureVac N.V's EBIT rose 11.84% to -$69.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $68.3 million, marking a year-over-year increase of 121.87%. This contributed to the annual value of $189.9 million for FY2024, which is 164.36% up from last year.
  • Per CureVac N.V's latest filing, its EBIT stood at $189.9 million for FY2024, which was up 164.36% from -$295.0 million recorded in FY2023.
  • In the past 5 years, CureVac N.V's EBIT registered a high of $189.9 million during FY2024, and its lowest value of -$471.6 million during FY2021.
  • Moreover, its 3-year median value for EBIT was -$254.5 million (2022), whereas its average is -$119.9 million.
  • Its EBIT has fluctuated over the past 5 years, first crashed by 260.20% in 2021, then spiked by 164.36% in 2024.
  • Over the past 5 years, CureVac N.V's EBIT (Yearly) stood at -$130.9 million in 2020, then plummeted by 260.20% to -$471.6 million in 2021, then spiked by 46.04% to -$254.5 million in 2022, then decreased by 15.92% to -$295.0 million in 2023, then surged by 164.36% to $189.9 million in 2024.